Agenus (AGEN) Other financing activities (2010 - 2022)

Agenus (AGEN) posted quarterly Other financing activities of $294000.0 for Q2 2022, down 97.06% quarter-over-quarter from $10.0 million in Q3 2021.

Agenus (AGEN) Other financing activities (2010 - 2022) Analysis & Trends

Agenus' Other financing activities history runs 12 years deep, the most recent figure standing at $294000.0 for Q2 2022.

In Q2 2022, Other financing activities changed N/A year-over-year to $294000.0; the TTM figure through Sep 2025 stood at $294000.0 (down 97.14% YoY), while the FY2024 annual figure was $73.9 million, changed N/A from the prior year.
Other financing activities for Q2 2022 stood at $294000.0, down from $10.0 million in the prior quarter.
The five-year high for Other financing activities was $203.8 million in Q3 2018, with the low at $172000.0 in Q1 2019.
The 4-year median for Other financing activities is $1.1 million (2018), against an average of $43.1 million.
The sharpest annual moves came in 2018 and 2019: Other financing activities soared 41367.86% in 2018, then slumped 83.79% in 2019.
Agenus' Other financing activities stood at $203.8 million in 2018, then tumbled by 99.92% to $172000.0 in 2019, then jumped by 5713.95% to $10.0 million in 2021, then sank by 97.06% to $294000.0 in 2022.
Business Quant data shows AGEN's Other financing activities at $294000.0 in Q2 2022, $10.0 million in Q3 2021, and $172000.0 in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Agenus	311.95 Mn	286.43 Mn	34.52 Mn

Download Data